Сравнительная характеристика эффективности разных миорелаксантов при реабилитации пациентов со спастичностью после инсульта

1. Гехт А.Б. Ишемический инсульт: вторичная профилактика и основные направления фармакотерапии в восстановительном периоде. Cons. Med. 2001; 5: 227–32.
2. Гудкова В.В., Стаховская Л.В., Кирильченко Т.Д. и др. Ранняя реабилитация после перенесенного инсульта. Cons. Med. 2005; 8: 692–6.
3. Дамулин И.В. Спастичность после инсульта. Рус. мед. журн. 2005; 7: 3–7.
4. Демиденко Т.Д., Ермакова Н.Г. Основы реабилитации неврологических больных. СПб.: Фолиант, 2004.
5. Кадыков А.С. Миорелаксанты при реабилитации больных с постинсультными двигательными нарушениями. Журн. неврол. и психиатр. им. С.С.Корсакова. 1997; 9: 53–5.
6. Окнин В.Ю. Баклофен в неврологической практике. Лечение нервных болезней. 2002; 3: 34–6.
7. Скворцова В.И., Ковражкина Е.А., Гудкова В.В. Биомеханические аспекты реабилитации больных с инсультами. Журн. неврол. и психиатр.. им. С.С.Корсакова. 2005; 7: 26–32.
8. Сорокоумов В.А. Методические рекомендации по организации неврологической помощи больным с инсультами в Санкт-Петербурге. СПб.: Человек, 2002.
9. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–2.
10. Bhakta B, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychitr 1996; 61: 30–5.
11. Behari M. Spasticity. Neurology India 2002; 50: 235–7.
12. Burt AA, Currie S. A double-blind controlled trial of baclofen and diazepam in spasticity due to cerebrovascular lessions. Spasticity and cerebral Pathology. Ed. A.M.Jukes. Cambridge: Cambridge Medical Publications, 1978; p. 77–9.
13. Dulin J, Kovacs L, Ramm S et al. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 1998; 31: 137–42.
14. Emre P. New development in the medical treatment of spasticity. Spasticity: Mechanisms and Management. Ed. A.F.Thilmann, D.J.Burke, W.Z.Rymer. Berlin–Heidelberg–New York: Springer, 1993; p. 372–84.
15. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998; 15 (4): 241–51.
16. Haas BM, Bergstrom E, Jamous A, Bennie A. The inter rater reliability of the original and of the modified Ashworth Scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord 1996; 34: 560–4.
17. Haque A, Hossain M, Khan JK et al. New findings and symptomatic treatment for neurolathyrism, a motor neuron disease in north west Bangladesh. Paraplegia 1994; 32: 570–2.
18. Hulme A, Mc Lennan WJ, Ritchie RT et al. Baclofen in the elderly stroke patient – its side-effects and pharmacokinetics. Eur L Clin Pharmacol 1985; 29: 467–9.
19. Katrak PH, Cole AMD, Poulos CJ, McCauley JCK. Objective assessment of spasticity, strength and function with early exhibition of Dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil 1992; 73: 4–9.
20. Kohnen R, Kriifer HP, Dulin J. Die humanexperimentelle Unlersuchung sedierender Wirkungen von Medik-amenten im Zusammenwirken mit Alkohol. Psychologic 1995; 21: 768–75.
21. Kwantabisa N. Occupational therapy ADL checklist self maintenance. Merton and Sutton Community NHS Trust. Stroke Rehabilitation Team Protocol (London) 1999; p. 7–9.
22. Lindmark B. Evaluation of functional capacity after stroke with special emphasis on motor function and activities of daily living. Scand J Rehabil Med (Suppl.) 1988; 21: 1–40.
23. Machoney F, Barthel D. Functional evalution: the Barthel Index. Md State Med J 1965; 14: 61–5.
24. Mayer N.H. Spasticity and the stretch reflex. Muscle Nerve 1997; 20 (Suppl. 6): S1–S13.
25. O’Brien CF, Seeberger LC, Smith DB. Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging 1996; 9: 332–40.
26. Pratzel HG, Alken RG, Rainm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain 1996; 67: 417–25.
27. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke 1985; 16: 885–90.
28. Stamenova P, Koytchev R, Kuhn K et al. A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol 2005; 12: 453–61.
29. Warlow CP, Dennis MS, van Gijn J et al. Stroke. A practical guide to management. London: Blackwell Science, 1997.
30. Winkler P.A. Assessment tools in the management of spasticity: Perspective from physical therapy. Physiology and Management of Spasticity. Ed. C.O’Brien. Deerfield, 1996; p. 3–14.

В.В.Ковальчук1, А.А.Скоромец2, И.В.Васильева2

1 ГУЗ Городская больница №38 им. Н.А.Семашко, Санкт-Петербург;
2  Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова